Parnell Pharmaceuticals Holdings Return on Investment 2014-2018 | PARNF
Current and historical return on investment (ROI) values for Parnell Pharmaceuticals Holdings (PARNF) over the last 10 years.
| Parnell Pharmaceuticals Holdings ROI - Return on Investment Historical Data |
| Date |
TTM Net Income |
LT Investments & Debt |
Return on Investment |
| 2018-03-31 |
$0.01B |
$0.02B |
42.11% |
| 2016-12-31 |
$0.01B |
$0.03B |
78.87% |
| 2016-09-30 |
$0.01B |
$0.02B |
66.67% |
| 2015-12-31 |
$0.01B |
$0.03B |
65.57% |
| 2015-09-30 |
$0.01B |
|
55.38% |
| 2015-06-30 |
$0.01B |
$0.04B |
43.08% |
| 2014-12-31 |
$0.00B |
$0.03B |
18.60% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.000B |
$0.000B |
|
Parnell Pharmaceuticals Holdings Ltd. is a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing animal health solutions. It manufactures and markets cattle reproduction, cattle mastitis, anesthetics, laminitis treatment, and orthopedic treatment products. The Company operates in four segments: Companion Animal, Production Animal-Unites States, and Production Animal-rest of the world and Manufacturing Operations. ZYDAX (R), GLYDE (R) and TERGIVE (R) are Parnell's premium osteoarthritis product suite. Parnell Pharmaceuticals Holdings Ltd. is headquartered in Alexandria, Australia.
|
